Department Of Hematology and Oncology
Alexander Wei, MD
Dr. Wei is an Assistant Professor of Medicine and Medical Oncologist specializing in the treatment of prostate, bladder, kidney, and other genitourinary cancers at the Herbert Irving Comprehensive Cancer Center at Columbia University. In addition to his clinical responsibilities, he is also a clinical trial investigator within the Genitourinary Oncology Research Program and the Phase 1 Experimental Therapeutics Program where he seeks to identify novel cancer treatments to improve patient outcomes.

Alexander Z. Wei, MD, received his Bachelor of Science and Master of Science in Immunology, Microbiology, and Virology at the University of Rochester. He then earned his medical degree from the John A. Burns School of Medicine at the University of Hawaii with a distinction in medical education. Following medical school, Dr. Wei completed both his Internal Medicine residency and Medical Oncology fellowship at Columbia University Irving Medical Center, where he was awarded the Dr. Joseph N. Muschel Housestaff Award and also served as chief fellow. During his fellowship, he focused on the identification and use of novel therapies in lung cancer and melanoma through early-phase clinical trials. He was selected to attend the ASCO/AACR Methods in Clinical Trials Research workshop where he further developed his acumen in clinical trial design. For his work in identifying uveal melanoma patients at risk for developing brain metastases, Dr. Wei was awarded the Jed Ian Taxel Rare Cancer Foundation Young Investigator Award. After discovering an interest in genitourinary oncology, his research now aims to utilize new treatments in locally advanced, muscle-invasive bladder cancer patients to potentially reduce the burden of surgery and the identification of novel agents to improve survival and quality of life in patients with advanced urothelial cancers.

Clinical Studies Managed By This Investigator:
Condition Study Title
Cancer [ CLOSED ] A Study for Patients with Advanced Solid Tumors Using Study Drug BMS-986207
Sarcoma [ CLOSED ] A Study of the Addition of APX005M to Doxorubicin in Patients with Advanced Sarcoma
Cancer [ CLOSED ] Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Cancer Study of IDE196 in Patients with Solid Tumors
Squamous Cell Carcinoma [ CLOSED ] Study of Ruxolitinib in Solid Organ Transplant Recipients with Advanced Cutaneous Squamous Cell Carcinoma
Melanoma [ CLOSED ] Study of SD-101 in Patients with Metastatic Uveal Melanoma (Eye Cancer) with Liver Disease
Melanoma [ CLOSED ] A First-in-Human Study Using FHD-286 in Patients with Metastatic Uveal Melanoma
Melanoma Study of DYP688 in Patients with Melanoma
Bladder Cancer Study of BT8009 in Combination with Pembrolizumab in Patients with Urothelial Cancer